Aclaris Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Aclaris Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue18.7231.2529.756.766.484.236.15
Cost of Revenue2.793.4211.9648.5334.474.064.33
Gross Profit15.9327.8317.79-41.77-27.990.171.82
Operating Expenses
Research & Development33.5998.3877.8143.8129.3464.9060.84
Selling, General & Administrative22.2032.4125.1323.6220.5327.8325.76
Operating Expenses157.86130.80102.9523.6220.5392.7386.60
Operating Income-141.93-97.36-89.85-65.38-48.52-111.06-84.78
Other Income/Expense
Interest Income7.958.510.000.000.000.000.00
Interest Expense0.000.000.000.000.000.000.00
Other Income/Expense9.87-26.90-1.75-1.14-0.426.542.68
Income
Income Before Tax-132.07-88.85-86.91-90.87-51.34-113.54-82.10
Income Tax Expense0.00-0.370.000.00-0.180.000.00
Net Income-132.07-88.48-86.91-90.87-51.02-161.35-132.74
Net Income - Continuous Operations-132.07-88.48-86.91-90.870.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-51.72-87.99-84.36-65.06-48.20-107.05-82.90
EBIT-132.07-88.85-85.15-65.38-48.52-113.46-84.78
Depreciation & Amortization0.810.800.700.320.321.500.00
Earnings Per Share
Basic EPS-2.00-1.00-1.00-2.00-1.00-4.00-4.00
Diluted EPS-2.00-1.00-1.00-2.00-1.00-4.00-4.00
Basic Shares Outstanding77.3069.8165.2156.7342.5441.3232.91
Diluted Shares Outstanding77.3069.8165.2156.7342.5441.3232.91